Latest Olanzapine Stories

A study published this week in PLOS Medicine finds that while antipsychotic medications are associated with small-to-moderate improvements in depressive symptoms in adults, there is little evidence for improvement on measures of quality of life and these medications are linked to adverse events such as weight gain and sedation. The results of the study, conducted by Glen Spielmans of Metropolitan State University in St. Paul, Minnesota and colleagues, have potential implications for the...

In older adults, antipsychotic drugs are commonly prescribed off-label for a number of disorders outside of their Food and Drug Administration (FDA)-approved indications – schizophrenia and bipolar disorder. The largest number of antipsychotic prescriptions in older adults is for behavioral disturbances associated with dementia, some of which carry FDA warnings on prescription information for these drugs. In a new study – led by researchers at the University of California, San Diego...

WOODCLIFF LAKE, N.J., Nov. 28, 2012 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that its Par Pharmaceutical, Inc. operating subsidiary has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for olanzapine and fluoxetine hydrochloride capsules, 3 mg/25 mg (eq base), 6 mg/25 mg (eq base), 6 mg/50 mg (eq base), 12 mg/25 mg (eq base) and 12 mg/50 mg (eq base). Olanzapine and fluoxetine hydrochloride is the...

INDIANAPOLIS, Oct. 24, 2012 /PRNewswire/ -- Worldwide revenue declined 11 percent to $5.443 billion, driven by Zyprexa patent expirations. Cymbalta revenue increased 16 percent due to continued growth in both the U.S. and international markets. Third-quarter earnings per share were $1.18 (reported), or $0.79 (non-GAAP, when excluding income from Amylin payment and asset impairment and restructuring charge). Data read-outs provided a better understanding of several potential...

INDIANAPOLIS, July 25, 2012 /PRNewswire/ -- Worldwide revenue declined 10 percent to $5.6 billion, driven by Zyprexa patent expirations, partially offset by significant growth in other products. Cymbalta revenue increased 22 percent due to continued strong growth in both the U.S. and international markets. China and Japan delivered pharma revenue growth of 28 percent and 15 percent, respectively, providing counter-cyclical growth. Elanco Animal Health continued its strong...

NEW YORK, July 18, 2012 /PRNewswire/ -- Drugs.com, the leading online clinical drug resource, today released first quarter 2012 U.S. prescription sales data for the top 100 drugs. Blood-thinners, proton-pump inhibitors, antipsychotics and asthma therapeutic categories continue to remain top sellers. Top Five Drugs by Sales, Q1 2012 Drug Name Sales ($000) % Change (previous quarter) --------- -----------...

TORONTO, July 17, 2012 /PRNewswire/ - Scientists have discovered two genetic variants associated with the substantial, rapid weight gain occurring in nearly half the patients treated with antipsychotic medications, according to two studies involving the Centre for Addiction and Mental Health (CAMH). These results could eventually be used to identify which patients have the variations, enabling clinicians to choose strategies to prevent this serious side-effect and offer more...

A study that examined maternal use of antipsychotic drugs during pregnancy suggests that these medications may be linked to an increased risk of gestational diabetes, according to a report in the July issue of Archives of General Psychiatry, a JAMA Network publication. Severe mental illnesses, such as schizophrenia and bipolar disorder, are usually treated with continuous antipsychotic drugs, "however, the evidence concerning use of antipsychotics during pregnancy is generally lacking or...

HOLLYWOOD, Calif., May 16, 2012 /PRNewswire/ -- Medbox, Inc. (Pinksheets: MDBX) (www.medboxinc.com) announced today that the company is developing a new, highly secure, automated kiosk for the storage of medicine supplies within doctor's offices. The system, which uses biometric fingerprint recognition, safely stores medicines and only allows authorized individuals to obtain access. The system also provides a permanent record of each retrieval - archiving the name of the...

INDIANAPOLIS, April 25, 2012 /PRNewswire/ -- Worldwide revenue declined 4 percent in the first quarter of 2012, driven by Zyprexa patent expirations, partially offset by significant growth in other products and key regions. Cymbalta revenue increased 23 percent due to strong growth in both the U.S. and international markets, while Effient revenue more than doubled. Elanco Animal Health revenue grew 33 percent, driven by gains in both the food animal and companion animal...